▶ Freely access a vast video library on NASH and NAFLD, its management and diagnosis along with the latest on pan-PPAR agonist, lanifibranor.
Nash Videos
NASH Treatment in 2022: Review of Current and Future Therapies for Non-Alcoholic Steatohepatitis
Prof. Stephen Harrison (USA) reviews current and future therapies for Non-Alcoholic Steatohepatitis (NASH). After a focus on the pathogenesis of NASH and the different pathways on how underlying steatohepatitis is developed, he presents his expert perspective on how patient outcomes can be improved.
View More ⏩
Psychological aspects of health behaviours in NAFLD non-alcoholic fatty liver disease
Prof. Maya Balakrishnan (USA) discusses the importance of the behavioural psychology in the field of non-alcoholic fatty liver disease, NAFLD.
View More ⏩
NASH Management in 2022: benefits of lifestyle recommendations, including nutrition and exercise
Prof. Stephen Harrison (USA) discusses state of the art management of non-alcoholic steatohepatitis (NASH) in 2022. He focuses on the benefits of lifestyle recommendations, including nutrition and exercise. He shows that weight loss is associated with NASH resolution and fibrosis regression over time following bariatric surgery in patients with severe obesity and NASH.
View More ⏩
Getting to the Heart of NAFLD and NASH – The international CVD Perspective (part. 4)
This video presents a comprehensive review of non-alcoholic fatty liver disease (NAFLD) & non-alcoholic steatohepatitis (NASH), delivered by international experts with a multidisciplinary approach: Dr. Maarten Tushuizen, Prof. A.G (Onno) Holleboom, and Prof. Sven Francque, along with chair, Prof. Stefan Anker. They review the epidemiology of NAFLD / NASH, its increasing prevalence rates, and discuss current best practices to improve patient outcomes.
View More ⏩
GETTING TO THE HEART OF NAFLD/NASH – THE CVD PERSPECTIVE (PART 3)
In this video, Prof. Sven Francque (Belgium) discusses how vascular mechanisms contribute to non-alcoholic fatty liver disease (NAFLD) and how non-alcoholic steatohepatitis (NASH) contributes to cardiovascular disease (CVD). He also mentions that drugs used to prevent/treat CVD and NAFLD/NASH are safe and those that are used to prevent/treat CVD can have some benefits for NAFLD.
View More ⏩
Getting to the heart of nafld/nash – the cvd perspective (part 2)
Prof. Onno Holleboom reviews the strong co-occurence of non-alcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular (CVD) disease in this video along with joint pathophysiological pathways and its shared drivers. He further looks into NAFLD and its relationships and effects with atherosclerotic CVD and heart failure. For clinicians, he provides an analyses of the management and diagnosis options for advanced NAFLD.
View More ⏩
GETTING TO THE HEART OF NAFLD/NASH – THE CVD PERSPECTIVE (PART 1)
Prof. Maarten Tushuizen provides a comprehensive review on Non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) and why it is a multisystem disease and further goes on to evaluate their connection to type 2 diabetes mellitus (T2DM) and cardiovascular disease. He also delves into the next steps of managing and diagnosing NASH and NAFLD.
View More ⏩
5Th Global Nash Congress
This slides set presents a detailed review of vascular alterations in non-alcoholic steatohepatitis (NASH) and NASH cirrhosis delivered by Professor Francque, MD, PhD. He highlights that non-fibrotic non-alcoholic fatty liver disease (NAFLD) is accompanied by a significant rise in portal pressure. Professor Francque, also explains the effects of intrahepatic vascular resistance increase in NAFLD. To the clinicians, he provides various patient studies, statistics and clinical data on the subject.
View More ⏩
Going beyond the liver in NAFLD/NASH: hepatologist’s / endocrinologist’s perspective
This multidisciplinary discussion on the diabetologist's and hepatologist's perspectives of non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH), involves international experts, Dr. Maarten Tushuizen, Prof. A.G (Onno) Holleboom and Prof. Christophe Moreno, together with the chair, Professor Manuel Castor Cabezas. The review addresses NAFLD as a multisystem disease, its epidemiology globally and the significance of developing multidisciplinary care paths.
View More ⏩
Non-Invasive Evaluation of NAFLD Severity
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are a leading cause of liver diseases worldwide, including hepatocellular carcinoma (HCC). In this review on non-invasive evaluation, Prof. Jérôme Boursier, France, presents a meta analysis focusing on the identification of patients with high risk profile and in need of specific management. Dr. Boursier reviews the two major families of non-invasive tests and discusses the sequential use of tests recommended in the EASL guidelines 2021.
View More ⏩
NIT for screening, referral & diagnosis of NAFLD
Liver fibrosis is the major driver in liver disease progression. Prof. Romero-Gómez, Spain, reviews on NoninvasiveTests - NITs for screening, referral, and diagnosis of nonalcoholic fatty liver disease.
View More ⏩
NAFLD/NASH as a metabolic disease: improving patients outcomes
Prof. Maarten Tushuizen, Netherlands, discusses the current treatment strategies for non-alcoholic fatty liver disease (NAFLD) and explains as well as future therapeutic approaches. Non-invasive tests (NITs) for staging the continuum of NAFLD / NASH are critical as well as establishing effective care pathways.
View More ⏩
SUBSCRIBE & FOLLOW US
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES